Irbesartan Viatris (Irbesartan)

Irbesartan is used in the management of conditions related to the renin‑angiotensin system, primarily hypertension and diabetic kidney disease.

• Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk.
• Diabetic nephropathy: slows progression of renal impairment and decreases proteinuria.
• Kidney disease in type 2 diabetes: helps preserve glomerular filtration rate and delays the need for dialysis.

• Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors on vascular smooth‑muscle cells, adrenal glands and renal tubular cells. By preventing angiotensin II binding, it inhibits vasoconstriction, aldosterone release, and sympathetic activation, leading to vasodilation, reduced sodium and water retention, and lower blood pressure. The blockade also diminishes intraglomerular pressure, providing renal protective effects in diabetic patients.

Irbesartan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate intensity.
• Fatigue: feeling unusually tired or weak.
• Upper respiratory tract infection: symptoms such as sore throat or nasal congestion.
• Mild hyperkalemia: slight increase in serum potassium levels.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue or throat, potentially compromising breathing.
• Severe hyperkalemia: markedly elevated potassium that may cause cardiac arrhythmias.
• Acute renal failure: sudden loss of kidney function, indicated by rising creatinine.
• Hepatic injury: abnormal liver enzymes or jaundice.
• Significant hypotension: abnormally low blood pressure leading to dizziness or fainting.

When prescribing Irbesartan, clinicians should consider several safety measures and monitoring requirements.

• Monitor blood pressure: ensure therapeutic reduction without excessive hypotension.
• Assess renal function: check serum creatinine and eGFR before initiation and periodically thereafter.
• Check serum potassium: especially in patients receiving potassium‑sparing agents or with renal impairment.
• Avoid use in pregnancy: category D, risk of fetal toxicity.
• Use caution in elderly or hepatic impairment: dose adjustments may be needed.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Aliskiren in patients with diabetes: combined use may increase renal risk.
• Potassium‑sparing diuretics or supplements: heightened risk of hyperkalemia.
• Concomitant ACE inhibitors: increased chance of angioedema and renal dysfunction.

Moderate Interactions (Monitor Closely)

• NSAIDs: may blunt antihypertensive effect and affect renal function.
• Lithium: Irbesartan can raise lithium concentrations, risking toxicity.
• CYP2C9 inhibitors (e.g., fluconazole): may increase Irbesartan plasma levels.
• Thiazide diuretics: can enhance blood‑pressure lowering effect; monitor electrolytes.